AP2764A - Hydroxylated nebivolol metabolites - Google Patents
Hydroxylated nebivolol metabolitesInfo
- Publication number
- AP2764A AP2764A AP2007004089A AP2007004089A AP2764A AP 2764 A AP2764 A AP 2764A AP 2007004089 A AP2007004089 A AP 2007004089A AP 2007004089 A AP2007004089 A AP 2007004089A AP 2764 A AP2764 A AP 2764A
- Authority
- AP
- ARIPO
- Prior art keywords
- nebivolol metabolites
- hydroxylated nebivolol
- hydroxylated
- metabolites
- nebivolol
- Prior art date
Links
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical class C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64855105P | 2005-01-31 | 2005-01-31 | |
US75585606P | 2006-01-03 | 2006-01-03 | |
PCT/US2006/003252 WO2006083779A2 (fr) | 2005-01-31 | 2006-01-30 | Metabolites de nebivolol hydroxyles |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2007004089A0 AP2007004089A0 (en) | 2007-08-31 |
AP2764A true AP2764A (en) | 2013-09-30 |
Family
ID=36676042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2007004089A AP2764A (en) | 2005-01-31 | 2006-01-30 | Hydroxylated nebivolol metabolites |
Country Status (12)
Country | Link |
---|---|
US (2) | US20070014733A1 (fr) |
EP (1) | EP1848424B1 (fr) |
JP (1) | JP2008528626A (fr) |
KR (1) | KR20080016527A (fr) |
AP (1) | AP2764A (fr) |
AU (1) | AU2006210952B2 (fr) |
CA (1) | CA2596426A1 (fr) |
IL (1) | IL184894A (fr) |
NZ (1) | NZ560386A (fr) |
RU (1) | RU2433823C2 (fr) |
SG (1) | SG175477A1 (fr) |
WO (1) | WO2006083779A2 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2731298T3 (es) | 2005-05-27 | 2019-11-14 | Univ North Carolina Chapel Hill | Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas |
PL2099790T3 (pl) * | 2006-11-27 | 2010-12-31 | Zach System Spa | Sposób wytwarzania nebiwololu |
BRPI0719367B8 (pt) * | 2006-11-27 | 2021-05-25 | Fis Fabbrica Italiana Sintetici Spa | processo para a preparação de nebivolol, seus intermediários e usos |
EP2120919B1 (fr) * | 2006-12-18 | 2012-08-29 | Cardoz AB | Nouvelle association destinée à être utilisée dans le traitement de troubles inflammatoires |
KR20090125077A (ko) * | 2007-03-30 | 2009-12-03 | 카르도스 아베 | 염증 질환 치료를 위한 새로운 조합 |
WO2009007680A2 (fr) | 2007-07-11 | 2009-01-15 | Cardoz Ab | Nouvelle combinaison destinée à être utilisée dans le traitement de troubles inflammatoires |
CA2720547A1 (fr) * | 2008-04-07 | 2009-10-15 | Cardoz Ab | Nouvelle combinaison pour une utilisation dans le traitement de troubles inflammatoires |
HUP0800498A2 (en) * | 2008-08-06 | 2010-03-29 | Semmelweis Egyetem | Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level |
EP2334279A4 (fr) * | 2008-10-16 | 2013-03-20 | Novan Inc | Particules libérant du monoxyde d'azote utilisables en hygiène bucco-dentaire |
EP2462144B1 (fr) | 2009-08-07 | 2017-09-20 | Merck Sharp & Dohme Corp. | Procede de preparation d'une 5-amino-pyrazolo-[4, 3-e]-1,2,4-triazolo [1,5-c] pyrimidine 2-alkynyl substituee |
CA2771389C (fr) | 2009-08-21 | 2019-04-09 | Novan, Inc. | Pansements, procedes d'utilisation de ceux-ci et procedes de formation de ceux-ci |
EP4249001A3 (fr) | 2009-08-21 | 2023-11-29 | Novan, Inc. | Gels topiques |
US20110086234A1 (en) * | 2009-10-13 | 2011-04-14 | Nathan Stasko | Nitric oxide-releasing coatings |
USD661900S1 (en) | 2010-02-22 | 2012-06-19 | Bajer Design & Marketing, Inc. | Collapsible structure |
WO2011132140A2 (fr) * | 2010-04-20 | 2011-10-27 | Cadila Pharmaceuticals Limited | Procédé de conversion du (2r)-6-fluoro-2-[(2s)-oxiran-2-yl]-3,4-dihydro-2h-chromène en (2r)-6-fluoro-2-[(2r)-oxiran-2-yl]-3,4-dihydro-2h-chromène |
WO2012027557A1 (fr) | 2010-08-26 | 2012-03-01 | The Regents Of The University Of Colorado, A Body Corporate | Inhibition sélective de récepteurs β1-adrénergiques pour le traitement de l'insuffisance cardiaque pédiatrique |
TR201903101T4 (tr) | 2010-09-01 | 2019-03-21 | Genzyme Corp | Miyokard enfarktüsün TGF-beta antagonistleri kullanılarak tedavisi. |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
WO2012118829A2 (fr) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Xérogels libérant de l'oxyde nitrique modifiés par des groupements s-nitrosothiols tertiaires et procédés d'utilisation associés |
NZ724002A (en) * | 2012-05-18 | 2017-07-28 | Luoda Pharma Pty Ltd | Liquid formulation comprising propylene glycol and an ace inhibitor |
US9592215B2 (en) * | 2015-08-05 | 2017-03-14 | Synergistic Therapeutics, Llc | Topical analgesic lotion |
IL242380A0 (en) | 2015-10-29 | 2016-02-01 | Yeda Res & Dev | A method for inducing the division of cardiomyocytes and treating heart diseases |
KR102203229B1 (ko) * | 2016-01-08 | 2021-01-14 | 에리슨제약(주) | 용출률이 개선된 네비보롤을 포함하는 약학적 조성물 |
WO2017119629A1 (fr) * | 2016-01-08 | 2017-07-13 | 에리슨제약(주) | Composition pharmaceutique comprenant du nébivolol à taux de dissolution amélioré |
US11324717B2 (en) * | 2016-06-22 | 2022-05-10 | Microbial Research Management Health Nv | Microbial carotenoids affecting gut microbial composition |
JOP20190219A1 (ar) * | 2017-05-09 | 2019-09-22 | Cardix Therapeutics LLC | تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية |
EA202090763A1 (ru) | 2017-11-15 | 2020-08-03 | Борис Славинович ФАРБЕР | Фармацевтическая композиция для стимуляции деления стволовых клеток и подавления вирулентности бактерий |
US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0334429A1 (fr) * | 1988-03-23 | 1989-09-27 | Janssen Pharmaceutica N.V. | Médicaments hypotenseurs |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2503059A (en) * | 1950-04-04 | Nxchj | ||
US2484029A (en) * | 1945-12-21 | 1949-10-11 | Ciba Pharm Prod Inc | Hydrazine derivatives of pyridazine compounds |
US2928829A (en) * | 1959-08-31 | 1960-03-15 | Ciba Pharm Prod Inc | Alkyleneimino-lower alkyl-guanidines |
DE1154810B (de) * | 1961-04-01 | 1963-09-26 | Knoll Ag | Verfahren zur Herstellung basisch substituierter Phenylacetonitrile |
NL300886A (fr) * | 1962-11-23 | |||
US3511836A (en) * | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
US3836671A (en) * | 1969-02-21 | 1974-09-17 | Ici Ltd | Alkanolamine derivatives for producing beta-adrenergic blockade |
GB1285038A (en) * | 1969-02-21 | 1972-08-09 | Ici Ltd | Alkanolamine derivatives |
SE354851B (fr) * | 1970-02-18 | 1973-03-26 | Haessle Ab | |
US3910924A (en) * | 1972-04-13 | 1975-10-07 | Otsuka Pharma Co Ltd | 3,4-Dihydrocarbostyril derivatives and a process for preparing the same |
US4105776A (en) * | 1976-06-21 | 1978-08-08 | E. R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
US4316906A (en) * | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
IL58849A (en) * | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
US4508729A (en) * | 1979-12-07 | 1985-04-02 | Adir | Substituted iminodiacids, their preparation and pharmaceutical compositions containing them |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (da) * | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US4344949A (en) * | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
ZA817261B (en) * | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
US4337201A (en) * | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
US4410520A (en) * | 1981-11-09 | 1983-10-18 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
GB2128984B (en) * | 1982-05-12 | 1985-05-22 | Hoffmann La Roche | Diaza-bicyclic compounds |
US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
US4654362A (en) * | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
CA1337429C (fr) * | 1983-12-05 | 1995-10-24 | Guy Rosalia Eugene Van Lommen | Derives du 2,2'-imino-bis-ethanol |
US4780401A (en) * | 1984-04-09 | 1988-10-25 | Ciba-Geigy Corporation | Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications |
US4845079A (en) * | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
US5066643A (en) * | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
US5387413A (en) * | 1985-06-14 | 1995-02-07 | The Research Foundation Of State University Of New York | Method of inhibiting thrombus formation by the 7E3 monoclonal antibody |
US5256687A (en) * | 1985-09-09 | 1993-10-26 | Hoechst Aktiengesellschaft | Pharmaceutical composition for the treatment of high blood pressure |
US4894437A (en) * | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
US4816463A (en) * | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
US5116870A (en) * | 1986-06-23 | 1992-05-26 | Merck & Co., Inc. | HMG-CoA reductase inhibitors |
US4940727A (en) * | 1986-06-23 | 1990-07-10 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
US4772684A (en) * | 1987-01-20 | 1988-09-20 | Triton Biosciences, Inc. | Peptides affecting blood pressure regulation |
US4904646A (en) * | 1987-05-22 | 1990-02-27 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-COA reductase inhibitors |
US5017716A (en) * | 1987-05-22 | 1991-05-21 | E.R. Squibb & Sons, Inc. | Phosphorous-containing HMG-CoA reductase inhibitors, new intermediates and method |
US5091378A (en) * | 1987-05-22 | 1992-02-25 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method |
US4906624A (en) * | 1987-09-08 | 1990-03-06 | Warner-Lambert Company | 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
US4997837A (en) * | 1987-09-08 | 1991-03-05 | Warner-Lambert Company | 6-(((substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
US5089471A (en) * | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
US4980283A (en) * | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
US5034512A (en) * | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
US5063207A (en) * | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
US5055466A (en) * | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
US4929620A (en) * | 1987-12-10 | 1990-05-29 | Warner-Lambert Company | 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis |
US5001144A (en) * | 1987-12-21 | 1991-03-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors |
US5001128A (en) * | 1987-12-21 | 1991-03-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | HMG-COA reductase inhibitors |
US4939143A (en) * | 1987-12-21 | 1990-07-03 | Rorer Pharmaceutical Corporation | Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors |
US4900754A (en) * | 1987-12-21 | 1990-02-13 | Rorer Pharmaceutical Corp. | HMG-COA reductase inhibitors |
US4994494A (en) * | 1987-12-21 | 1991-02-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | HMG-COA reductase inhibitors |
US5081127A (en) * | 1988-01-07 | 1992-01-14 | E. I. Du Pont De Nemours And Company | Substituted 1,2,3-triazole angiotensin II antagonists |
US4946864A (en) * | 1988-02-01 | 1990-08-07 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
US5036054A (en) * | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
DE68914495T2 (de) * | 1988-03-02 | 1994-10-27 | Merck & Co Inc | Antihypercholesterolemisches Mittel. |
US5021453A (en) * | 1988-03-02 | 1991-06-04 | Merck & Co., Inc. | 3-keto HMG-CoA reductase inhibitors |
US6545040B1 (en) | 1988-03-23 | 2003-04-08 | Janssen Pharmaceutica N.V. | Method of lowering the blood pressure |
US4920109A (en) * | 1988-04-18 | 1990-04-24 | Merck & Co., Inc. | Antifungal compositions and method of controlling mycotic infections |
US5166171A (en) * | 1988-05-13 | 1992-11-24 | Hoechst Aktiengesellschaft | 6-phenoxymethyl-4-hydroxytetrahydropyran-2-ones and 6-thiphenoxymethyl-4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acid derivatives, salts and esters, and in treating hypercholesterolemia |
US5036053A (en) * | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
US4897402A (en) * | 1988-06-29 | 1990-01-30 | Merck & Co., Inc. | 5-oxa, 5-thia, 5-aza HmG-CoA reductase inhibitors |
US4963538A (en) * | 1988-06-29 | 1990-10-16 | Merck & Co., Inc. | 5-oxygenated HMG-CoA reductase inhibitors |
IT1226726B (it) * | 1988-07-29 | 1991-02-05 | Zambon Spa | Composti attivi come inibitori della biosintesi del colesterolo. |
US5196440A (en) * | 1988-07-29 | 1993-03-23 | Zambon Group S.P.A. | Compounds active as inhibitors of the cholesterol biosynthesis |
DE3841520A1 (de) * | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
US4957940A (en) * | 1988-12-21 | 1990-09-18 | Warner-Lambert Company | Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis |
US4906657A (en) * | 1988-12-21 | 1990-03-06 | Warner-Lambert Company | Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis |
US4950675A (en) * | 1988-12-21 | 1990-08-21 | Warner-Lambert Company | Pyridine di-mevalono-lactones as inhibitors of cholesterol biosynthesis |
US5106835A (en) * | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
US4923861A (en) * | 1989-02-07 | 1990-05-08 | Warner-Lambert Company | 6-(2-(2-(Substituted amino)-3-quinolinyl) ethenyl and ethyl) tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
US5130306A (en) * | 1989-03-13 | 1992-07-14 | Merck & Co., Inc. | 5-Oxygenated HMG-COA reductase inhibitors |
US5132312A (en) * | 1989-03-27 | 1992-07-21 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors |
DE4004820A1 (de) * | 1989-08-05 | 1991-04-25 | Bayer Ag | Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln |
US5064825A (en) * | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
US4970231A (en) * | 1989-06-09 | 1990-11-13 | Merck & Co., Inc. | 4-substituted HMG-CoA reductase inhibitors |
US5102911A (en) * | 1989-06-09 | 1992-04-07 | Merck & Co, Inc. | 4-Substituted HMG-CoA reductase inhibitors |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5063208A (en) * | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
US4992429A (en) * | 1989-08-24 | 1991-02-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Novel HMG-COA reductase inhibitors |
US5098931A (en) * | 1989-08-31 | 1992-03-24 | Merck & Co., Inc. | 7-substituted HMG-CoA reductase inhibitors |
US5098924A (en) * | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
US5104869A (en) * | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
US4946860A (en) * | 1989-11-03 | 1990-08-07 | Rorer Pharmaceutical Corporation | Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors |
US5114937A (en) * | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
US5073566A (en) * | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
IT1237793B (it) * | 1989-12-21 | 1993-06-17 | Zambon Spa | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
US5025000A (en) * | 1990-03-02 | 1991-06-18 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-CoA reductase inhibitor compounds |
US5095119A (en) * | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
US5064965A (en) * | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
US5075451A (en) * | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US5085992A (en) * | 1990-07-19 | 1992-02-04 | Merck & Co., Inc. | Microbial transformation process for antihypertensive products |
US5112857A (en) * | 1990-09-04 | 1992-05-12 | Merck & Co., Inc. | Hmg-coa reductase inhibitor metabolites |
US5087634A (en) * | 1990-10-31 | 1992-02-11 | G. D. Searle & Co. | N-substituted imidazol-2-one compounds for treatment of circulatory disorders |
US5071837A (en) * | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
US5182298A (en) * | 1991-03-18 | 1993-01-26 | Merck & Co., Inc. | Cholesterol lowering agents |
US5256689A (en) * | 1991-05-10 | 1993-10-26 | Merck & Co., Inc. | Cholesterol lowering compounds |
US5135935A (en) * | 1991-05-17 | 1992-08-04 | Merck & Co., Inc. | Squalene synthetase inhibitors |
US5250435A (en) * | 1991-06-04 | 1993-10-05 | Merck & Co., Inc. | Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I) |
US5705583A (en) * | 1991-07-05 | 1998-01-06 | Biocompatibles Limited | Polymeric surface coatings |
US5202327A (en) * | 1991-07-10 | 1993-04-13 | E. R. Squibb & Sons, Inc. | Phosphorus-containing hmg-coa reductase inhibitors |
HU217629B (hu) * | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
US5260332A (en) * | 1992-02-07 | 1993-11-09 | Merci & Co., Inc. | Cholesterol lowering compounds |
US5262435A (en) * | 1992-02-10 | 1993-11-16 | Merck & Co., Inc. | Cholesterol lowering compounds |
US5286895A (en) * | 1992-02-19 | 1994-02-15 | Merck & Co., Inc. | Cholesterol lowering compounds |
US5302604A (en) * | 1992-03-09 | 1994-04-12 | Merck & Co., Inc. | Cholesterol lowering compounds produced by directed biosynthesis |
US5369125A (en) * | 1992-07-17 | 1994-11-29 | Merck & Co., Inc. | Cholesterol-lowering agents |
US5283256A (en) * | 1992-07-22 | 1994-02-01 | Merck & Co., Inc. | Cholesterol-lowering agents |
US5317031A (en) * | 1992-10-19 | 1994-05-31 | Merck & Co., Inc. | Cholesterol lowering compounds |
US5543297A (en) * | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
TW355683B (en) * | 1994-02-17 | 1999-04-11 | Janssen Pharmaceutica Nv | Composition containing micronized nebivolol |
KR100264348B1 (ko) * | 1994-12-28 | 2000-08-16 | 디르크 반테 | 항-죽종형성제로서 네비볼롤을 함유하는 조성물 |
US5770645A (en) * | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US5994444A (en) * | 1997-10-16 | 1999-11-30 | Medtronic, Inc. | Polymeric material that releases nitric oxide |
US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
AU780205B2 (en) * | 2000-02-23 | 2005-03-10 | Alteon Inc. | Thiazolium compounds and treatments of disorders associated with protein aging |
US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
-
2006
- 2006-01-30 AP AP2007004089A patent/AP2764A/xx active
- 2006-01-30 WO PCT/US2006/003252 patent/WO2006083779A2/fr active Application Filing
- 2006-01-30 KR KR1020077019852A patent/KR20080016527A/ko not_active Application Discontinuation
- 2006-01-30 RU RU2007132730/15A patent/RU2433823C2/ru active
- 2006-01-30 NZ NZ560386A patent/NZ560386A/en not_active IP Right Cessation
- 2006-01-30 SG SG2010030559A patent/SG175477A1/en unknown
- 2006-01-30 CA CA002596426A patent/CA2596426A1/fr not_active Withdrawn
- 2006-01-30 JP JP2007553331A patent/JP2008528626A/ja active Pending
- 2006-01-30 AU AU2006210952A patent/AU2006210952B2/en not_active Ceased
- 2006-01-30 US US11/342,497 patent/US20070014733A1/en not_active Abandoned
- 2006-01-30 EP EP06719896.0A patent/EP1848424B1/fr not_active Not-in-force
-
2007
- 2007-07-29 IL IL184894A patent/IL184894A/en active IP Right Grant
-
2010
- 2010-10-20 US US12/908,336 patent/US20110065783A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0334429A1 (fr) * | 1988-03-23 | 1989-09-27 | Janssen Pharmaceutica N.V. | Médicaments hypotenseurs |
Non-Patent Citations (6)
Title |
---|
BROEDERS MARTIJN A W ET AL: "Nebivolol: A third-generation beta-blocker that augments vascular nitric oxide release: Endothelial beta2-adrenergic receptor-mediated nitric oxide production" CIRCULATION, vol. 102, no. 6, 8 August 2000 (2000-08-08), pages 677-684, XP002393075 ISSN: 0009-7322 * |
COCKCROFT J: "Nebivolol: A review" EXPERT OPINION ON PHARMACOTHERAPY 2004 UNITED KINGDOM, vol. 5, no. 4, 2004, pages 893-899, XP009070520 ISSN: 1465-6566 * |
HENDRICKX J ET AL: "Location of the hydroxyl functions in hydroxylated metabolites of nebivolol in different animal species and human subjects as determined by on-line high-performance liquid chromatography-diode-array detection" JOURNAL OF CHROMATOGRAPHY A, ELSEVIER, AMSTERDAM, NL, vol. 729, no. 1, 5 April 1996 (1996-04-05), pages 341-354, XP004039196 ISSN: 0021-9673 * |
MCNEELY W ET AL: "NEBIVOLOL IN THE MANAGEMENT OF ESSENTIAL HYPERTENSION: A REVIEW" DRUGS, ADIS INTERNATIONAL LTD, AT, vol. 57, no. 4, April 1999 (1999-04), pages 633-651, XP009057403 ISSN: 0012-6667 * |
STOSCHITZKY K ET AL: "Different effects of exercise on plasma concentrations of nebivolol, bisoprolol and carvedilol" CARDIOVASCULAR DRUGS AND THERAPY 2004 UNITED STATES, vol. 18, no. 2, 2004, pages 135-138, XP002393073 ISSN: 0920-3206 * |
VAN PEER A ET AL: "Clinical pharmacokinetics of nebivolol. A review" DRUG INVESTIGATION 1991 NEW ZEALAND, vol. 3, no. SUPPL. 1, 1991, pages 25-30, XP009069916 ISSN: 0114-2402 * |
Also Published As
Publication number | Publication date |
---|---|
US20110065783A1 (en) | 2011-03-17 |
AP2007004089A0 (en) | 2007-08-31 |
EP1848424B1 (fr) | 2017-04-05 |
SG175477A1 (en) | 2011-11-28 |
KR20080016527A (ko) | 2008-02-21 |
CA2596426A1 (fr) | 2006-08-10 |
JP2008528626A (ja) | 2008-07-31 |
WO2006083779A3 (fr) | 2006-11-23 |
RU2007132730A (ru) | 2009-03-10 |
US20070014733A1 (en) | 2007-01-18 |
WO2006083779A2 (fr) | 2006-08-10 |
NZ560386A (en) | 2009-12-24 |
EP1848424A2 (fr) | 2007-10-31 |
RU2433823C2 (ru) | 2011-11-20 |
IL184894A0 (en) | 2007-12-03 |
AU2006210952B2 (en) | 2011-08-04 |
IL184894A (en) | 2012-10-31 |
AU2006210952A1 (en) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2764A (en) | Hydroxylated nebivolol metabolites | |
AP2672A (en) | Glucuronidate nebivoloi metabolites | |
EP2114895A4 (fr) | Métabolites de talarazole | |
EP1799011A4 (fr) | Haut-parleur | |
GB0523904D0 (en) | Bag-in-shell (BIS) | |
TWI316377B (en) | Stage mechanism | |
ZA200706285B (en) | Hydroxylated nebivolol metabolites | |
EP1921842A4 (fr) | Piédestal | |
ZA200801986B (en) | Standard | |
AU304197S (en) | Pedestal | |
AU305473S (en) | Support | |
GB2428267B (en) | Support member | |
GB0418869D0 (en) | Box support | |
GB0502086D0 (en) | Expandable plate | |
GB0605591D0 (en) | Support | |
GB0512782D0 (en) | Supports | |
TWM292452U (en) | Nail-linked structure for puncher | |
GB2422066B (en) | Loudspeaker | |
GB0512977D0 (en) | Loudspeaker cabinet | |
GB0503932D0 (en) | Loudspeaker | |
GB0521112D0 (en) | Loudspeaker | |
GB0515099D0 (en) | Loudspeaker | |
AU2005900245A0 (en) | Enclosure | |
GB0506432D0 (en) | Support | |
GB0521193D0 (en) | Support |